A new preclinical trial revealed the efficacy and IND/CTA enabling studies with ARM210/S48168. ARMGO Pharma and Servier are set to initiate clinical trials for the treatment of Duchenne Muscular Dystrophy (DMD). The companies have been working on a drug called Rycals®. Rycals targets the Ryanodine Receptor (RyR), an intracellular calcium…
Parent Project Muscular Dystrophy (PPMD) has partnered with Swiss pharmaceutical company Santhera Pharmaceuticals to conduct a collaborative study on the benefits and risks of Duchenne muscular dystrophy therapies. The researchers, which will use data from Santhera’s phase 3 clinical trial of idebenone, will be focused on determining…
Biopharmaceutical company Prosensa announced that they will present at the 6th annual conference on RNA Therapeutics, which will take place between February 16 and 17, 2015 in London, and will discuss the latest developments of its investigational drug for the treatment of Duchenne muscular dystrophy. Prosensa, which earlier…
Sarepta Therapeutics Inc. has announced that it will host a webcast and conference call dedicated specifically to the Duchenne muscular dystrophy (DMD) community, as the company is dedicated to the development of novel RNA-based therapies for the treatment of the genetic and disabling disease. The webcast and conference will take place on Tuesday, December…
Newport Beach-based Coalition Duchenne has granted its 2014 Lotus Award to professor Rachelle Crosbie-Watson from the University of California, Los Angeles (UCLA) in recognition of her outstanding work in education, research, and awareness for Duchenne muscular dystrophy. The award also includes a $10,000 grant, which will be given to the Center for Duchenne Muscular Dystrophy at…
The Kennedy Krieger Institute in Baltimore, Maryland has been granted Certified Duchenne Care Center status by the Parent Project Muscular Dystrophy (PPMD) advocacy group. The institute is the fifth institution to receive the designation, which recognizes its dedication to the improvement of healthcare services for patients suffering from Duchenne muscular dystrophy. Along with the…
Biopharmaceutical company PTC Therapeutics was honored with the Outstanding Innovation Award at The 2014 Rare & Orphan Advocacy & Research Awards. The prize was granted to PTC for their lead therapy Translarna, which has recently become the first treatment for Duchenne muscular dystrophy to be approved in the European…
The International Duchenne Alliance has announced that it will provide a $500,000 grant to researchers Jerry Mendell, M.D. and Milo Biotechnology to support their work in a first ever follistatin gene therapy trial for Duchenne muscular dystrophy. The study will be held at Mendell at Nationwide Children’s Hospital in Columbus, Ohio, and the…
The national nonprofit organization CureDuchenne and biotechnology company Prosensa Holding, both of which are committed to finding a cure for Duchenne muscular dystrophy (DMD) in different ways, recently presented a collaborative project at the 6th annual Partnering for Cures event. The conference, which is wrapping up today in New York City, gathered about 1,000…
Researchers throughout the world continue to work towards improved treatments for Duchenne muscular dystrophy (DMD). In response to recent advancements in the lab, the Muscular Dystrophy Association has published their Fall 2014 drug development update, highlighting the most prominent and promising DMD research and drug development. Translarna (ataluren),…
Get regular updates to your inbox.